A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...